Volume | 16,662 |
|
|||||
News | - | ||||||
Day High | 1.04 | Low High |
|||||
Day Low | 0.98 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Alzamend Neuro Inc | ALZN | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
0.98 | 0.98 | 1.04 | 1.00 | 1.02 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
120 | 16,662 | US$ 1.00 | US$ 16,716 | - | 0.74 - 11.91 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
18:49:44 | 6 | US$ 1.02 | USD |
Alzamend Neuro Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
7.26M | 7.12M | - | 0 | -14.88M | -2.09 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Alzamend Neuro News
Date | Time | Source | News Article |
---|---|---|---|
3/07/2024 | 15:30 | Edgar (US Regulatory) | Form 8-K - Current report |
2/02/2024 | 15:30 | Edgar (US Regulatory) | Form 8-K - Current report |
1/05/2024 | 15:30 | Edgar (US Regulatory) | Form 8-K - Current report |
12/15/2023 | 15:30 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
12/11/2023 | 07:00 | Business Wire | Alzamend Neuro Receives FDA “Study May Proceed” Notification.. |
11/20/2023 | 07:00 | Business Wire | Alzamend Neuro Receives FDA “Study May Proceed” Notification.. |
11/16/2023 | 15:30 | Edgar (US Regulatory) | Form 8-K - Current report |
11/16/2023 | 07:00 | Business Wire | Alzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid.. |
11/13/2023 | 07:00 | Business Wire | Alzamend Neuro Submits IND Application for a Phase IIA.. |
10/30/2023 | 15:30 | Edgar (US Regulatory) | Form 8-K - Current report |
10/30/2023 | 07:00 | Business Wire | Alzamend Neuro Announces Reverse Stock Split |
10/23/2023 | 07:00 | Business Wire | Alzamend Neuro Submits IND Application for a Phase IIA.. |
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ALZN Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.04 | 1.1017 | 0.953601 | 1.02 | 40,237 | -0.04 | -3.85% |
1 Month | 0.94 | 1.29 | 0.9001 | 1.10 | 103,919 | 0.06 | 6.38% |
3 Months | 0.94 | 1.29 | 0.74 | 1.04 | 53,307 | 0.06 | 6.38% |
6 Months | 3.516 | 3.897 | 0.74 | 1.78 | 140,326 | -2.52 | -71.56% |
1 Year | 6.75 | 11.91 | 0.74 | 4.65 | 160,393 | -5.75 | -85.19% |
3 Years | 435.00 | 503.25 | 0.74 | 42.03 | 1,251,216 | -434.00 | -99.77% |
5 Years | 435.00 | 503.25 | 0.74 | 42.03 | 1,251,216 | -434.00 | -99.77% |
Alzamend Neuro Description
Alzamend Neuro Inc is an early clinical stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's. |